NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球特殊檢測市場(~2026 年):類型(傳染病/內分泌/腫瘤/毒性/免疫/基因檢測)/技術(MS/CLIA/ELISA/PCR)/最終用戶(獨立和參考實驗室/醫院)實驗室)□ 按地區

Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) - Global Forecast to 2026

出版商 MarketsandMarkets 商品編碼 1016662
出版日期 內容資訊 英文 240 Pages
訂單完成後即時交付
價格
全球特殊檢測市場(~2026 年):類型(傳染病/內分泌/腫瘤/毒性/免疫/基因檢測)/技術(MS/CLIA/ELISA/PCR)/最終用戶(獨立和參考實驗室/醫院)實驗室)□ 按地區 Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories, Hospital Laboratories) - Global Forecast to 2026
出版日期: 2021年06月25日內容資訊: 英文 240 Pages
簡介

在預測期內,全球專業檢測市場預計將以 11.6% 的複合年增長率增長,從 2021 年的 210 億美元增長到 2026 年的 363 億美元。我會的。

慢性病和傳染病發病率的增加、精準醫療和癌症的早期診斷以及在個性化醫療發展中更多地使用特殊的DNA測序技術等因素正在推動市場的增長。另一方面,缺乏贖回會抑制市場的進一步增長。

按類型劃分,傳染病檢測部門預計將在預測期內引領市場。傳染病的增加、分子診斷技術的創新以及新興國家醫療基礎設施的改善等因素預計將提高該行業的份額。增長率還預測,基因檢測部門將在同一時期以最高的複合年增長率增長。 NGS 等測序技術的進步和意識的提高正在推動該行業的發展。

本報告探討了全球專業檢測市場、市場定義和概述、冠狀病毒病 (COVID-19) 和其他市場影響因素的分析、市場規模趨勢和預測、類型。-按技術、總結了最終用戶和地區、競爭環境、主要公司的概況等。

第 1 章介紹

第二章調查方法

第 3 章執行摘要

第 4 章重要考慮事項

第 5 章市場概覽

  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
    • 挑戰
  • COVID-19:影響分析
  • COVID-19 的影響
  • 監管概覽
  • 技術分析
  • 平均售價
  • 專利分析
  • 價值鏈分析
  • 供應鏈分析
  • 生態系統分析
  • 顛覆性技術
  • 波特五力分析

第 6 章市場分析/預測:按類型

  • 傳染病檢測
  • 內分泌檢查
  • 腫瘤檢查
  • 基因檢測
  • 毒性試驗
  • 免疫測試
  • 神經系統檢查
  • 其他

第 7 章市場分析/預測:按技術

  • CLIA(化學發光免疫分析)
  • ELISA
  • 質譜
  • 實時 PCR
  • DNA 測序
  • 流式細胞術
  • 其他

第 8 章市場分析/預測:按最終用戶

  • 獨立實驗室參考實驗室
  • 醫院實驗室

第 9 章市場分析/預測:按地區/主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第10章競爭形勢

  • 概述
  • 大公司的成功戰略
  • 收入分析
  • 市場份額分析
  • 企業評估象限
  • 企業評估象限:中小企業/初創公司
  • 競爭基準
  • 競爭場景/趨勢

第 11 章公司簡介

  • 主要公司
    • LABCORP
    • QUEST DIAGNOSTICS
    • OPKO HEALTH, INC.
    • H.U. GROUP HOLDINGS, INC.
    • HEALIUS LIMITED
    • SONIC HEALTHCARE LIMITED
    • MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH(MFMER)
    • EUROFINS SCIENTIFIC
    • STANFORD HEALTH CARE(STANFORD CLINICAL PATHOLOGY)
    • FOUNDATION MEDICINE, INC.
    • KINDSTAR GLOBAL(BEIJING)TECHNOLOGY, INC.
    • ARUP LABORATORIES
    • GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC
    • THYROCARE TECHNOLOGIES LIMITED
    • ACM GLOBAL LABORATORIES
  • 其他有力企業
    • BIOAGILYTIX LABS
    • BP DIAGNOSTIC CENTRE SDN. BHD.
    • NMS LAB
    • BAYLOR ESOTERIC AND MOLECULAR LABORATORY
    • HEALTHQUEST ESOTERICS
    • CERBA XPERT
    • BUHLMANN DIAGNOSTICS CORP
    • LEO LABS, INC.
    • FLOW HEALTH

第12章 附錄

目錄
Product Code: MD 5930

The global esoteric testing market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period. Market growth is largely driven by the rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and advancements in the personalized medicine. Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market. In contrast, inadequate reimbursements of the esoteric test may restrict market growth to a certain extent. The esoteric testing market is segmented based on type, technology, end user and region.

"Infectious disease testing segment is expected to dominate the market during the forecast period and the genetic testing segment is also expected to grow at the highest CAGR during the forecast period."

Based on product, the esoteric testing market is segmented into infectious disease testing, endocrinology testing, oncology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing. Infectious disease testing segment accounted the largest share of the esoteric testing market. The largest share of the segment is attributed to the increasing incidence of infectious diseases, technological innovations in molecular diagnostics, and improving healthcare infrastructure in developing nations. The genetic testing segment is expected to register the highest CAGR during the forecast period. The fastest growth of the genetic testing segment is attributed to the advancements in the sequencing technologies such as NGS and increasing awareness.

"CLIA segment to dominate the market during the forecast period."

Based on technology, esoteric testing market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), mass spectrometry, real-time PCR, flow cytometry, DNA sequencing, and other technologies. CLIA accounted for the largest share of the esoteric testing market in 2020. The large share of this segment can be attributed to its advantages over other testing methods, such as high-performance levels, low detection limits, higher specificity, high signal intensity, and good precision.

"Independent & reference laboratories segment to dominate the market during the forecast period."

Based on end user, the esoteric testing market is segmented into independent & reference laboratories and hospital-based laboratories. Independent & reference laboratories account for the largest share of the esoteric testing market. The largest share is attributed to the high testing volumes. In addition, the ongoing automation, and digitalization of diagnostic laboratories, growing number of accredited laboratories, significant reimbursement coverage, and the competitive benefits offered by these providers are pushing the growth of the segment.

"North America will dominate the market during the forecast period."

Geographically, the esoteric testing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the esoteric testing market. The large share of the North American market can be attributed to the increasing per capita healthcare expenditure, presence of the leading market players, increasing use of rapid diagnostics, expanding geriatric population, and advancing precision medicine in the region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1: 48%, Tier 2: 40%, and Tier 3: 12%
  • By Designation - C-level: 26%, D-level: 30%, and Others: 44%
  • By Region - North America: 34%, Europe: 26%, Asia Pacific: 23%, and Rest of the World: 17%

List of Companies Profiled in the Report

  • Labcorp (US)
  • Quest Diagnostics (US)
  • OPKO Health (US)
  • H.U. Group Holdings, Inc. (Japan)
  • Healius Limited (Australia)
  • Sonic Healthcare (Australia)
  • Mayo Foundation for Medical Education and Research (MFMER, US)
  • Eurofins Scientific (Luxembourg)
  • Stanford Clinical Pathology (US)
  • Foundation Medicine (US)
  • Kindstar Global (Beijing) Technology, Inc. (China)
  • ARUP Laboratories (US)
  • Georgia Esoteric & Molecular Laboratory, LLC (US)
  • Thyrocare Technologies Ltd. (India)
  • ACM Global Laboratories (US)
  • BioAgilytix Labs (US)
  • National Medical Services Inc. (NMS) (US)
  • Baylor Esoteric and Molecular Laboratory (US)
  • Cerba Xpert (Belgium)
  • HealthQuest Esoterics (US)
  • BUHLMANN Diagnostics Corp (BDC, US)
  • BP Diagnostic Centre SDN BHD (Malaysia)
  • Flow Health (US)
  • Leo Labs, Inc. (India).

Research Coverage:

This report provides a detailed picture of the global esoteric testing market. It aims at estimating the size and future growth potential of the market across different segments, such as type, technology, end user and region. The report also analyzes factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total esoteric testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on esoteric testing services offered by the top 24 players in the esoteric testing market. The report analyses the esoteric testing market by type, technology, end user and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various esoteric testing services across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the esoteric testing market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the esoteric testing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY
  • 1.3 MARKET SEGMENTATION
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 ESOTERIC TESTING MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 ESOTERIC TESTING MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF ESOTERIC TESTING SERVICES
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 7 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.3.1 SECONDARY DATA
    • 2.3.2 PRIMARY DATA
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY
    • 2.5.1 COVID-19-SPECIFIC ASSUMPTIONS
  • 2.6 LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT
  • 2.8 COVID-19 ECONOMIC ASSESSMENT
  • 2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
    • FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
    • FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY

    • FIGURE 11 ESOTERIC TESTING MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)
    • FIGURE 12 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD BILLION)
    • FIGURE 13 ESOTERIC TESTING MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
    • FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE ESOTERIC TESTING MARKET

4 PREMIUM INSIGHTS

  • 4.1 ESOTERIC TESTING MARKET OVERVIEW
    • FIGURE 15 RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY AND COUNTRY (2020)
    • FIGURE 16 ELISA SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MARKET IN 2020
  • 4.3 ESOTERIC TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE ESOTERIC TESTING MARKET FROM 2021 TO 2026
  • 4.4 ESOTERIC TESTING MARKET: REGIONAL MIX (2021-2026)
    • FIGURE 18 APAC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
  • 4.5 ESOTERIC TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 19 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 ESOTERIC TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing geriatric population and the increasing prevalence of chronic and infectious diseases
    • FIGURE 21 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
    • FIGURE 22 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
    • TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
    • FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
    • TABLE 4 ESOTERIC TESTS INDICATED FOR CHRONIC AND INFECTIOUS DISEASES
      • 5.2.1.2 Increasing use of esoteric DNA sequencing technologies in precision medicine and the early diagnosis of cancer
      • 5.2.1.3 Advancements in esoteric tests for personalized medicine
      • 5.2.1.4 Increasing research funding for precision medicine, genetic analysis, and personalized medicine
      • 5.2.1.5 Growing number of collaborations in the esoteric testing market
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Inadequate reimbursement
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging technologies in esoteric testing
      • 5.2.3.2 Growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Dearth of skilled professionals
  • 5.3 COVID-19 IMPACT ANALYSIS
    • 5.3.1 COVID-19 HEALTH ASSESSMENT
    • FIGURE 24 COVID-19 GLOBAL PROPAGATION
  • 5.4 IMPACT OF COVID-19 ON THE ESOTERIC TESTING MARKET
    • FIGURE 25 KEY PLAYERS: REVENUE IMPACT
  • 5.5 REGULATORY OVERVIEW
    • TABLE 5 STRINGENCY OF REGULATIONS FOR CLINICAL LABORATORY ACCREDITATION, BY COUNTRY
    • 5.5.1 NORTH AMERICA
      • 5.5.1.1 US
      • 5.5.1.2 Canada
    • 5.5.2 EUROPE
    • TABLE 6 ACCREDITATION BODIES IN EUROPE
    • 5.5.3 ASIA PACIFIC
      • 5.5.3.1 Japan
      • 5.5.3.2 India
      • 5.5.3.3 China
  • 5.6 TECHNOLOGY ANALYSIS
    • TABLE 7 KEY PLAYERS OFFERING ESOTERIC TESTS WITH ADVANCED TECHNOLOGIES
  • 5.7 AVERAGE SELLING PRICE TREND
    • TABLE 8 AVERAGE SELLING PRICE OF ESOTERIC TESTS, 2021
  • 5.8 PATENT ANALYSIS
    • FIGURE 26 LIST OF MAJOR PATENTS FOR THE ESOTERIC TESTING
    • FIGURE 27 REGIONAL ANALYSIS OF PATENTS GRANTED FOR THE ESOTERIC TESTING MARKET, 2015-2020
    • TABLE 9 INDICATIVE LIST OF ESOTERIC TESTING PATENTS
  • 5.9 VALUE CHAIN ANALYSIS
    • FIGURE 28 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
  • 5.10 SUPPLY CHAIN ANALYSIS
    • FIGURE 29 DIRECT DISTRIBUTION IS THE PREFERRED STRATEGY FOR PROMINENT LABORATORIES
  • 5.11 ECOSYSTEM ANALYSIS OF THE ESOTERIC TESTING MARKET
    • FIGURE 30 ECOSYSTEM ANALYSIS OF THE ESOTERIC TESTING MARKET
    • 5.11.1 ROLE IN THE ECOSYSTEM
    • TABLE 10 ESOTERIC TESTING MARKET: ECOSYSTEM
    • FIGURE 31 KEY PLAYERS IN THE ESOTERIC TESTING MARKET ECOSYSTEM
  • 5.12 DISRUPTIVE TECHNOLOGIES IN THE MARKET
    • FIGURE 32 DISRUPTIVE TECHNOLOGIES IN THE ESOTERIC TESTING MARKET
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 11 HIGH FRAGMENTATION IN THE MARKET TO RESTRICT THE ENTRY OF NEW PLAYERS
    • 5.13.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.13.2 BARGAINING POWER OF SUPPLIERS
    • 5.13.3 BARGAINING POWER OF BUYERS
    • 5.13.4 THREAT OF SUBSTITUTES
    • 5.13.5 THREAT OF NEW ENTRANTS

6 ESOTERIC TESTING MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 12 ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
  • 6.2 INFECTIOUS DISEASE TESTING
    • 6.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    • TABLE 13 EXAMPLES OF ESOTERIC TESTS FOR INFECTIOUS DISEASES
    • TABLE 14 ESOTERIC INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 6.3 ENDOCRINOLOGY TESTING
    • 6.3.1 INCREASING INCIDENCE OF DIABETES TO DRIVE THE ADOPTION OF ESOTERIC TESTS
    • TABLE 15 ESOTERIC ENDOCRINOLOGY TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 6.4 ONCOLOGY TESTING
    • 6.4.1 RISING PREVALENCE OF CANCER TO DRIVE THE MARKET FOR ESOTERIC TESTING
    • TABLE 16 GLOBAL INCIDENCE OF CANCER IN MEN, 2020
    • TABLE 17 GLOBAL INCIDENCE OF CANCER IN WOMEN, 2020
    • TABLE 18 EXAMPLES OF ESOTERIC TESTS FOR THE DIAGNOSIS OF CANCER
    • TABLE 19 ESOTERIC ONCOLOGY TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 6.5 GENETIC TESTING
    • 6.5.1 ADVANCEMENTS IN GENOMICS AND PROTEOMICS TO SUPPORT MARKET GROWTH
    • TABLE 20 ESOTERIC GENETIC TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 6.6 TOXICOLOGY TESTING
    • 6.6.1 INCREASING CASES OF DRUG ABUSE AND ILLICIT DRUG CONSUMPTION HAVE INCREASED THE DEMAND FOR ESOTERIC TESTING
    • TABLE 21 ESOTERIC TOXICOLOGY TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 6.7 IMMUNOLOGY TESTING
    • 6.7.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 22 INCIDENCE OF AUTOIMMUNE DISEASES, BY TYPE
    • TABLE 23 EXAMPLES OF ESOTERIC TESTS AVAILABLE FOR IMMUNOLOGY TESTING
    • TABLE 24 ESOTERIC IMMUNOLOGY TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 6.8 NEUROLOGY TESTING
    • 6.8.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDER TO DRIVE MARKET GROWTH
    • TABLE 25 EXAMPLES OF ESOTERIC TESTS FOR NEUROLOGICAL DISORDERS
    • TABLE 26 ESOTERIC NEUROLOGY TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 6.9 OTHER TESTING
    • TABLE 27 OTHER ESOTERIC TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)

7 ESOTERIC TESTING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 28 ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
  • 7.2 CHEMILUMINESCENCE IMMUNOASSAY
    • 7.2.1 RISING GERIATRIC POPULATION TO AID MARKET GROWTH
    • TABLE 29 ESOTERIC TESTING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2026 (USD MILLION)
  • 7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
    • 7.3.1 GROWING NUMBER OF DRUG DISCOVERY ACTIVITIES TO DRIVE MARKET GROWTH
    • TABLE 30 EXAMPLES OF ESOTERIC ELISA TESTS
    • TABLE 31 ESOTERIC TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2026 (USD MILLION)
  • 7.4 MASS SPECTROMETRY
    • 7.4.1 MASS SPECTROMETRY IS USED IN ENDOCRINE TESTING AND INFECTIOUS DISEASE DIAGNOSIS
    • TABLE 32 EXAMPLES OF ESOTERIC MASS SPECTROMETRY TESTS
    • TABLE 33 ESOTERIC TESTING MARKET FOR MASS SPECTROMETRY, BY REGION, 2018-2026 (USD MILLION)
  • 7.5 REAL-TIME PCR
    • 7.5.1 INCREASING USE OF QPCR FOR VARIOUS DIAGNOSTIC AND RESEARCH PURPOSES TO DRIVE MARKET GROWTH
    • TABLE 34 ESOTERIC TESTING MARKET FOR REAL-TIME PCR, BY REGION, 2018-2026 (USD MILLION)
  • 7.6 DNA SEQUENCING
    • 7.6.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO AID MARKET GROWTH
    • TABLE 35 EXAMPLES OF ESOTERIC TESTS FOR DNA SEQUENCING
    • TABLE 36 ESOTERIC TESTING MARKET FOR DNA SEQUENCING, BY REGION, 2018-2026 (USD MILLION)
  • 7.7 FLOW CYTOMETRY
    • 7.7.1 RISING PREVALENCE OF CANCER, HIV, AND HEMATOLOGIC MALIGNANCIES TO DRIVE MARKET GROWTH
    • TABLE 37 ESOTERIC TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2018-2026 (USD MILLION)
  • 7.8 OTHER TECHNOLOGIES
    • TABLE 38 ESOTERIC TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2018-2026 (USD MILLION)

8 ESOTERIC TESTING MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 39 ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 8.2 INDEPENDENT & REFERENCE LABORATORIES
    • 8.2.1 INDEPENDENT & REFERENCE LABORATORIES ARE THE LARGEST END USERS OF ESOTERIC TESTS
    • TABLE 40 ESOTERIC TESTING MARKET FOR INDEPENDENT & REFERENCE LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
  • 8.3 HOSPITAL-BASED LABORATORIES
    • 8.3.1 HOSPITAL-BASED LABORATORIES ARE MORE ACCESSIBLE AND OFFER TEST RESULTS IN A SHORTER TIME PERIOD
    • TABLE 41 ESOTERIC TESTING MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2026 (USD MILLION)

9 ESOTERIC TESTING MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 42 ESOTERIC TESTING MARKET, BY REGION, 2018-2026 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 33 NORTH AMERICA: ESOTERIC TESTING MARKET SNAPSHOT
    • TABLE 43 NORTH AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
    • TABLE 44 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 45 NORTH AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 46 NORTH AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 The US dominates the North American esoteric testing market
    • TABLE 47 US: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
    • TABLE 48 US: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 49 US: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 50 US: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Lack of proper reimbursements for diagnostic tests to hamper the market growth
    • TABLE 51 CANADA: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 52 CANADA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 53 CANADA: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 54 EUROPE: ESOTERIC TESTING MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
    • TABLE 55 EUROPE: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 56 EUROPE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 57 EUROPE: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany held the largest share of the European esoteric testing market in 2020; this trend will continue in the forecast period
    • TABLE 58 GERMANY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
    • TABLE 59 GERMANY: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 60 GERMANY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 61 GERMANY: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.3.2 FRANCE
      • 9.3.2.1 Rising demand for early disease diagnosis to drive market growth
    • TABLE 62 FRANCE: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 63 FRANCE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 64 FRANCE: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.3.3 ITALY
      • 9.3.3.1 Rapidly growing geriatric population in Italy to favor market growth
    • TABLE 65 ITALY: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 66 ITALY: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 67 ITALY: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.3.4 UK
      • 9.3.4.1 The UK is the fastest-growing market for esoteric testing in Europe due to the favorable investment scenario in the country
    • TABLE 68 UK: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 69 UK: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 70 UK: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 High burden of chronic and infectious diseases in the country to drive the adoption of esoteric tests
    • TABLE 71 SPAIN: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 72 SPAIN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 73 SPAIN: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 74 ROE: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
    • TABLE 75 ROE: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
    • TABLE 76 ROE: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 77 ROE: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 78 ROE: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 34 ASIA PACIFIC: ESOTERIC TESTING MARKET SNAPSHOT
    • TABLE 79 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.4.1 JAPAN
      • 9.4.1.1 Presence of a well-developed healthcare system to favor market growth in Japan
    • TABLE 83 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
    • TABLE 84 JAPAN: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 85 JAPAN: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 86 JAPAN: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.4.2 CHINA
      • 9.4.2.1 China to register the highest growth rate in the esoteric testing market during the forecast period
    • TABLE 87 CHINA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
    • TABLE 88 CHINA: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 89 CHINA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 90 CHINA: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Improving healthcare system in the country to support market growth
    • TABLE 91 INDIA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
    • TABLE 92 INDIA: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 93 INDIA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 94 INDIA: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 95 ROAPAC: CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2040
    • TABLE 96 ROAPAC: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 97 ROAPAC: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 98 ROAPAC: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 9.5 LATIN AMERICA
    • TABLE 99 LATIN AMERICA: LUNG CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
    • TABLE 100 LATIN AMERICA: LIVER CANCER INCIDENCE, BY COUNTRY, 2018 VS. 2025
    • TABLE 101 LATIN AMERICA: ESOTERIC TESTING MARKET, BY COUNTRY, 2018-2026 (USD MILLION)
    • TABLE 102 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 103 LATIN AMERICA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 104 LATIN AMERICA: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.5.1 BRAZIL
      • 9.5.1.1 Brazil is the largest market for esoteric testing in Latin America
    • TABLE 105 BRAZIL: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 106 BRAZIL: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 107 BRAZIL: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.5.2 MEXICO
      • 9.5.2.1 Growth in the private healthcare sector to propel market growth
    • TABLE 108 MEXICO: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 109 MEXICO: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 110 MEXICO: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
    • 9.5.3 REST OF LATIN AMERICA
    • TABLE 111 ROLATAM: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 112 ROLATAM: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 113 ROLATAM: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 IMPROVEMENTS IN THE HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET FOR ESOTERIC TESTING IN THE MEA
    • TABLE 114 AFRICA: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025
    • TABLE 115 MEA: ESOTERIC TESTING MARKET, BY TYPE, 2018-2026 (USD MILLION)
    • TABLE 116 MEA: ESOTERIC TESTING MARKET, BY TECHNOLOGY, 2018-2026 (USD MILLION)
    • TABLE 117 MEA: ESOTERIC TESTING MARKET, BY END USER, 2018-2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY ESOTERIC TESTING LABORATORIES
  • 10.3 REVENUE ANALYSIS
    • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN THE ESOTERIC TESTING MARKET
  • 10.4 MARKET SHARE ANALYSIS
    • FIGURE 36 ESOTERIC TESTING MARKET SHARE ANALYSIS, 2020
    • TABLE 118 ESOTERIC TESTING MARKET: DEGREE OF COMPETITION
  • 10.5 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS)
    • 10.5.1 STARS
    • 10.5.2 PERVASIVE PLAYERS
    • 10.5.3 EMERGING LEADERS
    • 10.5.4 PARTICIPANTS
    • FIGURE 37 ESOTERIC TESTING MARKET (GLOBAL): COMPANY EVALUATION QUADRANT, 2020
  • 10.6 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 STARTING BLOCKS
    • 10.6.3 RESPONSIVE COMPANIES
    • 10.6.4 DYNAMIC COMPANIES
    • FIGURE 38 ESOTERIC TESTING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
  • 10.7 COMPETITIVE BENCHMARKING
    • 10.7.1 COMPANY TECHNOLOGY FOOTPRINT
    • 10.7.2 COMPANY TESTING FOOTPRINT
    • 10.7.3 COMPANY REGIONAL FOOTPRINT
    • 10.7.4 COMPANY FOOTPRINT
  • 10.8 COMPETITIVE SCENARIO AND TRENDS
    • 10.8.1 DEALS
    • TABLE 119 DEALS, JANUARY 2018-MAY 2021
    • 10.8.2 SERVICE LAUNCHES & APPROVALS
    • TABLE 120 SERVICE LAUNCHES & APPROVALS, JANUARY 2018-MAY 2021
    • 10.8.3 OTHER DEVELOPMENTS
    • TABLE 121 OTHER DEVELOPMENTS, JANUARY 2018-MAY 2021

11 COMPANY PROFILES

  • 11.1 MAJOR PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 11.1.1 LABCORP
    • TABLE 122 LABCORP: BUSINESS OVERVIEW
    • FIGURE 39 LABCORP: COMPANY SNAPSHOT (2020)
    • 11.1.2 QUEST DIAGNOSTICS
    • TABLE 123 QUEST DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 40 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2020)
    • 11.1.3 OPKO HEALTH, INC.
    • FIGURE 41 OPKO HEALTH: COMPANY SNAPSHOT (2020)
    • 11.1.4 H.U. GROUP HOLDINGS, INC.
    • TABLE 124 H.U. GROUP HOLDINGS, INC.: BUSINESS OVERVIEW
    • FIGURE 42 H.U. GROUP HOLDINGS, INC.: COMPANY SNAPSHOT (2019)
    • 11.1.5 HEALIUS LIMITED
    • TABLE 125 HEALIUS LIMITED: BUSINESS OVERVIEW
    • FIGURE 43 HEALIUS LIMITED: COMPANY SNAPSHOT (2020)
    • 11.1.6 SONIC HEALTHCARE LIMITED
    • TABLE 126 SONIC HEALTHCARE LIMITED: BUSINESS OVERVIEW
    • FIGURE 44 SONIC HEALTHCARE LIMITED: COMPANY SNAPSHOT (2020)
    • 11.1.7 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER)
    • FIGURE 45 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH: COMPANY SNAPSHOT (2020)
    • 11.1.8 EUROFINS SCIENTIFIC
    • TABLE 127 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
    • 11.1.9 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY)
    • TABLE 128 STANFORD HEALTH CARE (STANFORD CLINICAL PATHOLOGY): BUSINESS OVERVIEW
    • 11.1.10 FOUNDATION MEDICINE, INC.
    • TABLE 129 FOUNDATION MEDICINE, INC.: BUSINESS OVERVIEW
    • 11.1.11 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.
    • TABLE 130 KINDSTAR GLOBAL (BEIJING) TECHNOLOGY, INC.: BUSINESS OVERVIEW
    • 11.1.12 ARUP LABORATORIES
    • TABLE 131 ARUP LABORATORIES: BUSINESS OVERVIEW
    • 11.1.13 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC
    • TABLE 132 GEORGIA ESOTERIC & MOLECULAR LABORATORY, LLC: BUSINESS OVERVIEW
    • 11.1.14 THYROCARE TECHNOLOGIES LIMITED
    • TABLE 133 THYROCARE TECHNOLOGIES LIMITED: BUSINESS OVERVIEW
    • FIGURE 47 THYROCARE TECHNOLOGIES LIMITED: COMPANY SNAPSHOT (2020)
    • 11.1.15 ACM GLOBAL LABORATORIES
    • TABLE 134 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 BIOAGILYTIX LABS
    • 11.2.2 BP DIAGNOSTIC CENTRE SDN. BHD.
    • 11.2.3 NMS LAB
    • 11.2.4 BAYLOR ESOTERIC AND MOLECULAR LABORATORY
    • 11.2.5 HEALTHQUEST ESOTERICS
    • 11.2.6 CERBA XPERT
    • 11.2.7 BUHLMANN DIAGNOSTICS CORP
    • 11.2.8 LEO LABS, INC.
    • 11.2.9 FLOW HEALTH
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 12.2 DISCUSSION GUIDE
  • 12.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4 AVAILABLE CUSTOMIZATIONS
  • 12.5 RELATED REPORTS
  • 12.6 AUTHOR DETAILS